SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 16th, 2018 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), is entered into as of February 16, 2018 (the “Execution Date”), by and among BioSig Technologies, Inc., a Delaware corporation, with headquarters located at 12424 Wilshire Blvd., Suite 745, Los Angeles, California 90025 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 16th, 2018 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 16, 2018 (the “Execution Date”), is entered into by and between BIOSIG TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer” and collectively, the “Buyers”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Securities Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
BIOSIG TECHNOLOGIES, INC. 12424 Wilshire Blvd, Suite 745 Los Angeles, CA 90025Consent • February 16th, 2018 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus
Reference is made to that certain Securities Purchase Agreement, dated as of November 3, 2017 (the “Securities Purchase Agreement”), by and among BioSig Technologies, Inc., a Delaware corporation (the “Company”), and certain purchasers identified on the signature pages thereto, including the investors listed on the signature page hereto (the “Investors”), as amended to date, and that certain Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock of the Company, dated November 3, 2017 (the “Certificate”), as amended to date. All capitalized terms in this letter (the “Letter Agreement”) shall have the meanings assigned to them under the Securities Purchase Agreement, unless otherwise defined herein.
